Competent Cells Market is Expected to Grow at USD 2,318.6 Million By 2023
Growing demand for recombinant
proteins and molecular cloned products, advancement in molecular cloning
research with emergence of new technologies, and various government initiatives
and availability of funding for life science research are the key drivers
propelling the industry growth during the forecast period. Moreover, emerging
economies such as Latin America, Asia Pacific, & Africa provides
significant opportunity in this market. However, factors such as high cost of
cloning based research and shortage of skilled professionals for handling of
competent cells hinder the growth of this market in many parts of the globe.
Cloning is a process used to
produce genetically identical copies of a biological entity. These copies are
referred to as clones. Since last decade, researchers are cloning a wide range
of biological material namely genes, cells, tissues, or entire organisms. For
this, the natural competence of a cell or bacteria or genome is highly important
i.e. it must possess the ability to take up the external DNA naturally.
However, with some organism’s
inability to take up the external DNA and limitations associated with natural
competence have led to the development of artificially competent cells. These
artificial competent cells increase the reliability and efficiency of
transformation based experiments. Further, researchers used this artificially
mediated transformation for repairing genes and thereby contribute to genome
maintenance or acquisition of genetic diversity.
Request Sample Report:https://www.meticulousresearch.com/request-sample-report/?cp_id=3723
Global competent cells market is expected to reach USD 2,318.6 million by 2023, at a CAGR of
10.0% during the forecast period of 2018 to 2023.
Succeeding an extensive secondary
and primary research on competent cells and in-depth analysis of the market
scenario, the report carries out an impact analysis of the key industry
drivers, restraint, opportunities, and challenges in the market dynamics
segment.
pharmaceutical and
biotechnology industry commanded the largest share in the global competent
cells market in 2017, mainly due to higher adoption of competent cells by
pharmaceutical & biotechnology companies with growing demand for molecular
cloning with advancements in the cloning technologies, and rising investments
in research & development to fulfill the demand for protein based
therapeutics.
About Meticulous Research®
Meticulous Research® is
founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in
2013 as a private limited company under the Companies Act, 1956. Since its
incorporation, the company has become the leading provider of premium market
intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle
East & Africa.
Contact
Us:
Viren Shrivastava
Viren Shrivastava
AVP-
Global Sales and Marketing
Meticulous
Research®
Tel:
+1-646-781-8004
Email:
viren@meticulousresearch.com
Comments
Post a Comment